Moberg Pharma Beheer

Beheer criteriumcontroles 1/4

De CEO Moberg Pharma is Anna Ljung, benoemd in May2019, heeft een ambtstermijn van 5.5 jaar. De totale jaarlijkse vergoeding van { bedraagt SEK 3.51M, bestaande uit 56.6% salaris en 43.4% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.016% van de aandelen van het bedrijf, ter waarde SEK 128.59K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 5.1 jaar en 2 jaar.

Belangrijke informatie

Anna Ljung

Algemeen directeur

SEK 3.5m

Totale compensatie

Percentage CEO-salaris	56.6%
Dienstverband CEO	5.5yrs
Eigendom CEO	0.02%
Management gemiddelde ambtstermijn	5.1yrs
Gemiddelde ambtstermijn bestuur	2yrs

Recente managementupdates

Moberg Pharma AB (publ)'s (STO:MOB) CEO Will Probably Find It Hard To See A Huge Raise This Year

May 08

Recent updates

We're Hopeful That Moberg Pharma (STO:MOB) Will Use Its Cash Wisely

Sep 14

Moberg Pharma AB (publ)'s (STO:MOB) CEO Will Probably Find It Hard To See A Huge Raise This Year

May 08

Analyse CEO-vergoeding

Hoe is Anna Ljung's beloning veranderd ten opzichte van Moberg Pharma's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-SEK 18m
Jun 30 2024	n/a	n/a	-SEK 23m
Mar 31 2024	n/a	n/a	-SEK 23m
Dec 31 2023	SEK 4m	SEK 2m	-SEK 21m
Sep 30 2023	n/a	n/a	-SEK 18m
Jun 30 2023	n/a	n/a	-SEK 16m
Mar 31 2023	n/a	n/a	-SEK 16m
Dec 31 2022	SEK 3m	SEK 2m	-SEK 16m
Sep 30 2022	n/a	n/a	-SEK 17m
Jun 30 2022	n/a	n/a	-SEK 16m
Mar 31 2022	n/a	n/a	-SEK 16m
Dec 31 2021	SEK 2m	SEK 1m	-SEK 16m
Sep 30 2021	n/a	n/a	SEK 8m
Jun 30 2021	n/a	n/a	SEK 7m
Mar 31 2021	n/a	n/a	SEK 5m
Dec 31 2020	SEK 3m	SEK 2m	SEK 7m
Jun 30 2020	n/a	n/a	SEK 20m
Jun 30 2019	SEK 476k	SEK 151k	-SEK 8m

Compensatie versus markt: De totale vergoeding ($USD 321.37K ) Anna } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de Swedish markt ($USD 236.20K ).

Compensatie versus inkomsten: De vergoeding van Anna is gestegen terwijl het bedrijf verliesgevend is.

CEO

Anna Ljung (44 yo)

5.5yrs

Tenure

SEK 3,511,000

Compensatie

Ms. Anna Ljung, M.Sc. Econ., BA serves as Chairperson of Biosergen AB since June 14, 2024. She served as Chairman of The Board at OncoZenge AB (publ) until August 2023. She joined company since 2020.Ms. L...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Anna Ljung	Chief Executive Officer	5.5yrs	SEK 3.51m	0.016% SEK 128.6k
Marie Moberg	Co-Founder	18.7yrs	SEK 193.70k	geen gegevens
Mark Beveridge	Vice President of Finance	5.1yrs	geen gegevens	0.033% SEK 270.8k
Christina Erixon	Head of Pharmaceutical Development & Operations	less than a year	geen gegevens	geen gegevens
Amir Tavakkol	Chief Scientific Officer	no data	geen gegevens	geen gegevens
Gunilla Wengström	Senior Director of Sales & Marketing	5.8yrs	geen gegevens	geen gegevens
Anders Broijersen	Chief Medical Officer	2yrs	geen gegevens	0.000020% SEK 162.8
Robert Ehrl	Head of Supply	less than a year	geen gegevens	geen gegevens

5.1yrs

Gemiddelde duur

55.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van MOB is doorgewinterd en ervaren (gemiddelde ambtstermijn van 5.1 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Howard Maibach	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Jonas Ekblom	Director	less than a year	geen gegevens	geen gegevens
Hakan Wallin	Independent Director	1.5yrs	SEK 99.00k	geen gegevens
Nikolaj Sorensen	Independent Director	3.5yrs	SEK 170.00k	0.17% SEK 1.4m
Jan Faergemann	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Lennart Emtestam	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Johan Heilborn	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Bernt Lindelöf	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Kerstin Strinnholm	Independent Chairman of the Board	2.5yrs	SEK 360.00k	0.19% SEK 1.6m

2.0yrs

Gemiddelde duur

60.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van MOB wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 2 jaar), wat duidt op een nieuw bestuur.

Moberg Pharma Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

Moberg Pharma AB (publ), Annual General Meeting, May 22, 2025

Independent Director recently bought kr144k worth of stock

Independent Chairman of the Board exercised options to buy kr397k worth of stock.

High number of new and inexperienced directors

Moberg Pharma AB (Publ) Elects Jonas Ekblom as Board Member

Moberg Pharma AB (publ)'s (STO:MOB) CEO Will Probably Find It Hard To See A Huge Raise This Year

Recent updates

Consensus estimates of losses per share improve by 20%

Moberg Pharma AB (publ), Annual General Meeting, May 22, 2025

Moberg Pharma AB (publ) to Report First Half, 2025 Results on Aug 12, 2025

Moberg Pharma AB (publ) to Report Fiscal Year 2024 Results on Feb 11, 2025

We're Hopeful That Moberg Pharma (STO:MOB) Will Use Its Cash Wisely

New minor risk - Market cap size

Now 64% undervalued after recent price drop

Moberg Pharma AB (publ) Receives Information About Clinical Cure in a Subset of Patients in the Ongoing North American Phase 3 Study for MOB-015 Against Nail Fungus

Price target increased by 26% to kr29.00

Independent Director recently bought kr144k worth of stock

Independent Chairman of the Board exercised options to buy kr397k worth of stock.

High number of new and inexperienced directors

New major risk - Revenue and earnings growth

Now 22% undervalued

Moberg Pharma AB (Publ) Elects Jonas Ekblom as Board Member

Moberg Pharma AB (publ)'s (STO:MOB) CEO Will Probably Find It Hard To See A Huge Raise This Year

Moberg Pharma AB Announces MOB-015 Receives National Approvals for All Countries Included in the Decentralized Procedure

New major risk - Share price stability

Moberg Pharma (STO:MOB) Will Have To Spend Its Cash Wisely

Moberg Pharma Announces Leadership Changes

Moberg Pharma AB (publ) Appoints Nomination Committee

Moberg Pharma Completes Enrollment to the Phase 3 Study for Mob-015 in North America

New major risk - Shareholder dilution

Moberg Pharma AB (publ) Announces National Approval for MOB-015 in Sweden

Moberg Pharma AB (publ) to Report Fiscal Year 2023 Final Results on Apr 16, 2024

Moberg Pharma AB Announces That Mob-015 Has Receives National Approval in Ireland for the Treatment of Mild to Moderate Fungal Infections of the Nails in Adults

Moberg Pharma AB (publ) Announces Approval for Mob-015 in the European Union

New major risk - Market cap size

Moberg Pharma AB (Publ) Recommends for Approval in EU

High number of new and inexperienced directors

Moberg Pharma AB (Publ) Elects Håkan Wallin to the Board Members

Will Moberg Pharma (STO:MOB) Spend Its Cash Wisely?

Less than half of directors are independent

Moberg Pharma AB (publ) Appoints Anders Bröijersén as Chief Medical Officer and a Member of the Management Team

Moberg Pharma AB (publ), Annual General Meeting, May 16, 2023

Moberg Pharma AB (publ) Approves Board Appointments

Peter Wolpert and Fredrik Granström Step-Down from the Board

Moberg Pharma AB (Publ) Begins Patient Enrollment in North American Phase 3 Study

Moberg Pharma AB Announces Peter Wolpert and Fredrik Granström are Not Available for Re-Election

The Medical Products Agency in Sweden Will Be Reference Member State for Moberg Pharma's European Registration Application

Moberg Pharma AB Announces the Results from the North American Phase 3-Study with MOB-015 (topical terbinafine) for the Treatment of Onychomycosis

Moberg Pharma AB's Paid Subscription Units to Be Delisted

New 90-day low: kr6.40

Read This Before Selling Moberg Pharma AB (publ) (STO:MOB) Shares

New 90-day low: kr9.05

Market pulls back on stock over the past week

Moberg Pharma AB (publ) to Report Q1, 2021 Results on May 11, 2021

Moberg Pharma AB (publ) to Report Fiscal Year 2020 Results on Feb 09, 2021

Moberg Pharma AB (Publ) Appoints Nomination Committee

Moberg Pharma AB (publ), Annual General Meeting, May 18, 2021

New 90-day low: kr11.30

New 90-day low: kr13.52

Caret Pharma LLC entered into an agreement to acquire the assets of Fiber Choice® from Moberg Pharma AB (publ) (OM:MOB) for $6.7 million.

Moberg Pharma AB (publ)(OM:MOB) dropped from S&P Global BMI Index

New 90-day low - kr14.01

Earnings released

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd